文献速递外周动脉疾病

慢性肢体威胁性缺血长段股腘病变:腔内治疗与旁路手术长期结局比较

Comparison of Long Term Outcomes After Endovascular Treatment Versus Bypass Surgery in Chronic Limb Threatening Ischaemia Patients with Long Femoropopliteal Lesions.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2020-12-15

中位随访61个月,PTA/S组再干预率显著更高(44.68% vs 29.79%,p=.002),但大截肢率无显著差异(27.23% vs 22.13%,p=.17);OSB组总体并发症率显著更高(20.42% vs 5.96%,p<.001)。

要点

  • GLASS III-IV级股腘病变CLTI中,OSB长期再干预率低于PTA/S,但术后并发症更多。
  • 两组大截肢率无显著差异(PTA/S 27.23% vs OSB 22.13%,p=.17)。
  • OSB组总体并发症率20.42% vs PTA/S 5.96%(p<.001),伤口感染/血清肿需延长住院进一步治疗者7.65% vs 0%。

核心结论

  • 对于CLTI合并GLASS III-IV级股腘病变,旁路手术在长期再干预率方面似乎优于PTA/S,但术后并发症率显著更高。

研究设计与样本

  • 采用基线与血管造影协变量计算倾向评分,匹配后PTA/S组与OSB组各235条肢体进入分析。
  • 主要结局为患肢免于再干预和大截肢,次要结局为两组所有住院并发症。

主要发现

  • OSB组总体并发症率显著高于PTA/S组(20.42% vs 5.96%,p<.001)。
  • OSB组需延长住院和进一步治疗的伤口感染/血清肿率为7.65%,PTA/S组为0%(p<.001)。
  • 中位随访61个月,PTA/S组再干预率显著高于OSB组(44.68% vs 29.79%,p=.002)。
  • 两组大截肢率无显著差异(PTA/S 27.23% vs OSB 22.13%,p=.17)。

关键数值与推荐

  • 再干预率:PTA/S 44.68% vs OSB 29.79%(log rank检验,p=.002)。
  • 大截肢率:PTA/S 27.23% vs OSB 22.13%(log rank检验,p=.17)。
  • 总体并发症率:OSB 20.42% vs PTA/S 5.96%(p<.001)。
  • 伤口感染/血清肿需延长住院进一步治疗:OSB 7.65% vs PTA/S 0%(p<.001)。

临床怎么用

  • 在GLASS III-IV级股腘病变CLTI患者选择血运重建方式时,需权衡OSB更低的长期再干预率与更高的围手术期并发症风险。
  • 对于高手术并发症风险患者,PTA/S虽再干预率较高但围手术期并发症显著更少,可作为个体化选择。

局限性

  • 本研究为回顾性两中心设计,结论需正在进行的随机试验及前瞻性队列研究进一步证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There are currently two treatments available for patients with chronic limb threatening ischaemia (CLTI): open surgical bypass (OSB) and percutaneous transluminal angioplasty with/without stenting (PTA/S). The aim of this study was to compare short and long term outcomes between PTA/S and OSB in CLTI patients with long (GLASS grade III and IV) femoropopliteal disease. METHODS: This was a two centre retrospective study including all consecutive patients with CLTI undergoing first time lower extremity intervention at two distinct vascular surgical centres. Between 1 January 2012 and 1 January 2018, 1 545 CLTI consecutive limbs were treated for femoropopliteal GLASS grade III and IV lesions at two vascular surgical centres. Using covariables from baseline and angiographic characteristics, a propensity score was calculated for each limb. Thus, comparable patient cohorts (235 in PTA/S and 235 in OSB group) were identified for further analysis. The primary outcomes were freedom from re-intervention in the treated extremity and major amputation. Secondary outcomes were all hospital complications among the two patient groups. RESULTS: Total overall complication rates were significantly higher in the OSB group (20.42% vs. 5.96%, p < .001), especially wound infection/seroma rate that required prolonged hospitalisation and further treatment (7.65% vs. 0%, p < .001). After the median follow up of 61 months, re-intervention rates were significantly higher in the PTA/S group (log rank test, 44.68% vs. 29.79%, p = .002), but there was no significant difference in terms of major amputation rates between the two group of patients (log rank test, PTA/S 27.23% vs. OSB 22.13%, p = .17). CONCLUSION: Bypass surgery seems to be superior to PTA/S for GLASS grade III and IV femoropopliteal lesions in patients with CLTI in terms of long term re-intervention rates, but with considerably higher rates of post-operative complications. A larger cohort of patients in currently ongoing randomised trials, as well as prospective cohort studies are necessary to confirm these findings.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Zlatanovic P, Mahmoud AA, Cinara I, et al. Comparison of Long Term Outcomes After Endovascular Treatment Versus Bypass Surgery in Chronic Limb Threatening Ischaemia Patients with Long Femoropopliteal Lesions. Eur J Vasc Endovasc Surg. 2020. PMID: 33334672. doi:10.1016/j.ejvs.2020.11.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。